Industry News & Expert Tips

Biotechnology: Audit Focus on Development, Collaboration and Commercialisation

Industry-specific audit considerations, tailored procedures, and evidence points for Hong Kong audit teams.

Industry Overview

biotechnology auditHKFRS 15research and developmentHKAS 38impairment testingclinical trial accrualslicensing revenuegoing concern

Last updated: 16 September 2026

Biotechnology businesses often combine long development cycles, scientific uncertainty and capital-intensive operations with licensing, collaboration and product-revenue models. For Hong Kong auditors, a sound risk assessment should connect the business model, product pipeline, clinical and regulatory milestones, outsourced activities and funding profile to the relevant financial-statement assertions—not treat the sector as a conventional product business.

This article outlines general technical considerations under the HKFRS and HKSA framework. It is intended to support professional discussion, audit planning and the design of responsive procedures; the nature, timing and extent of work remain matters for professional judgment in the particular facts and circumstances.

Key Audit Issues

Collaboration, licence and milestone revenue

Collaboration arrangements may bundle licences to intellectual property, research or development services, supply commitments, royalties and milestone payments. Under the HKFRS 15 model, the audit focus is whether the entity has identified the promised goods or services appropriately, determined the transaction price—including constrained variable consideration—and recognised revenue as or when the relevant performance obligation is satisfied. Contract amendments, termination rights, territorial rights and principal-versus-agent considerations can materially alter the accounting conclusion.

Research and development expenditure, intangible assets and impairment

Biotechnology entities may incur substantial costs before a product is commercially viable. The distinction between research expenditure and development expenditure, and the point at which recognition criteria for a development intangible asset are met under HKAS 38, require evidence-based judgment. Capitalised programmes, licences and acquired technology may also require impairment consideration under HKAS 36 when clinical, regulatory, commercial or financing developments indicate that carrying amounts may not be recoverable.

Clinical-trial, contract-research and manufacturing accruals

Clinical research organisations, investigational sites, laboratories and contract manufacturers may bill after services have been performed. Completeness and cut-off of trial costs, manufacturing costs and related liabilities can therefore be significant risks. The audit team should understand how patient visits, enrolment, laboratory work, batch activity and contractual rates feed into period-end accruals, and whether management has distinguished executed activity from future commitments.

Inventory, product quality and net realisable value

For entities with diagnostic kits, biologics or other products, inventory may be held at third-party manufacturers or logistics providers and can be vulnerable to expiry, cold-chain or quality-release restrictions. The audit implications extend beyond physical existence to rights, condition, obsolescence, costing, cut-off and the lower-of-cost-and-net-realisable-value assessment under HKAS 2. Batch traceability and quality records can be relevant evidence.

Liquidity, going concern and pipeline-dependent forecasts

Pre-revenue or loss-making entities can depend on equity raises, partner funding and future programme milestones. Forecasts used in the going-concern assessment and in impairment models may be highly sensitive to financing availability, trial outcomes, approval timing and commercial assumptions. In applying the relevant HKSA requirements, auditors should evaluate management's assessment, test the supporting evidence for key assumptions and consider whether the financial-statement disclosures appropriately explain material uncertainty or significant judgment where applicable.

Tailored Audit Procedures

Build and test a contract-term matrix

Obtain significant collaboration, licensing, supply and distribution agreements and amendments. Trace material terms to a contract matrix, inspect approvals and correspondence, and evaluate management's analysis of promised goods or services, payment clauses, termination provisions, royalties and milestones. Test recorded revenue to the relevant contractual trigger and supporting evidence of transfer of control or progress of services.

Assess milestone and royalty accounting

For selected material milestones and royalty streams, inspect third-party notifications, study or regulatory milestone evidence, licensee reports and cash receipts where available. Reperform the calculation of consideration and evaluate whether variable amounts were included only to the extent consistent with the applicable HKFRS 15 constraint. Perform focused cut-off testing around reporting date for invoices, credit notes, contract amendments and subsequent events.

Test the R&D expenditure and capitalisation boundary

Obtain a project-by-project population of R&D costs and development intangibles. Vouch selected costs to payroll records, purchase orders, CRO invoices and project documentation; inspect management's stage-gate assessments and contemporaneous evidence supporting any capitalisation decision. Test whether costs that remain research in nature have been expensed and whether amortisation begins only when the asset is available for use.

Challenge impairment and recoverability models

For material intangible assets, licences or cash-generating units, evaluate whether indicators of impairment were identified and test the mathematical accuracy of management's model. Compare forecast assumptions with approved budgets, current trial status, available market evidence and post-year-end developments; assess consistency with other audit evidence; and perform sensitivity analysis on assumptions that drive headroom. Consider whether specialist input is needed for technical or valuation matters.

Substantiate clinical and outsourced-service accruals

Reconcile management's clinical-trial and outsourced-service accrual schedules to contracts, approved budgets and the general ledger. Test selected studies using CRO or site progress reports, patient-visit or laboratory activity data, monitoring records and subsequent invoices or payments. Recalculate selected accruals using contractual rates and performed activity, and investigate significant differences between accrued, invoiced and budgeted amounts.

Verify inventory, third-party custody and funding evidence

Observe inventory counts where practicable and test counts to lot or batch records; obtain confirmations or alternative evidence for material stock held by contract manufacturers or logistics providers. Inspect quality-release, expiry and subsequent-sales information when evaluating net realisable value. Separately, inspect bank confirmations, financing agreements, board minutes, cash-flow forecasts and post-year-end financing activity to assess the evidence supporting liquidity and going-concern conclusions.

The procedures are illustrative. The engagement team should tailor the nature, timing, and extent of its work to the assessed risks, materiality, relevant reporting framework, and facts of the engagement.

Controls and Evidence to Consider

Contract governance and revenue-accounting review

A cross-functional process should require legal, commercial and finance review of new or amended collaboration and licence agreements before accounting entries are made. Useful evidence includes executed agreements, a maintained contract-term matrix, documented accounting conclusions, authorised price or milestone changes, milestone certificates and periodic reconciliations of revenue to contract data and the ledger.

R&D project stage gates and capitalisation approvals

Management should maintain defined project stages, authorised budgets and documented technical and commercial assessments for decisions affecting the research/development boundary. Evidence may include approved development plans, technical-feasibility assessments, study protocols and reports, management or board approvals, project cost reports and documented reviews of useful lives and impairment indicators.

Clinical-trial and outsourced-cost accrual reconciliation

A monthly control can reconcile study activity from CROs, sites, laboratories and contract manufacturers to contracted rates, invoices received and accrual calculations, with review of unusual movements and stale accruals. Supporting evidence may include approved work orders, visit or enrolment reports, monitoring reports, vendor statements, invoice-status reports, reviewer sign-off and tracked follow-up of exceptions.

Batch traceability, quality status and inventory reconciliation

Inventory records should identify product, lot or batch, location, quantity, expiry date and quality-release status, and be reconciled to third-party custodian reports and the general ledger. Relevant evidence includes count instructions and results, independent count review, warehouse or manufacturer statements, batch manufacturing records, quality-release documentation, temperature-excursion investigations and expiry or obsolescence analyses.

Apply Industry Insight to Your Audit Workflow

EQC can discuss audit-quality priorities, documentation, inspection readiness, and Audit Program 4.1 (AP4.1) workflow support relevant to your practice.

Scroll to Top